SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25 Stock

DE000SU6Q4C8

Real-time Boerse Frankfurt Warrants 12:03:50 2024-06-03 EDT
0.88 ^EUR	-7.37%

1 month	+30.14%
3 months	+126.19%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	10:14am	BU
Bristol Myers: presents advances in lung cancer	08:58am	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	08:09am	BU
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.88	-7.37%
24-05-31	0.95	-5.00%
24-05-30	1	+1.01%
24-05-29	0.99	+1.02%
24-05-28	0.98	+8.89%

Real-time Boerse Frankfurt Warrants

Last update June 03, 2024 at 12:03 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU6Q4C
ISIN	DE000SU6Q4C8
Date issued	2024-01-08
Strike	50 $
Maturity	2025-03-21 (291 Days)
Parity	10 : 1
Emission price	0.46 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.02 €
Lowest since issue	0.29 €
Spread	0.01 €
Spread %	1.12%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company